Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of alzheimer's disease

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Goñi, Fernando ^a,c   Prelli, Frances ^a   Ji, Yong ^a   Scholtzova, Henrieta ^a   Yang, Jing ^a   Sun, Yanjie ^a   Liang, Feng Xia ^a   Kascsak, Regina ^b   Kascsak, Richard ^b   Mehta, Pankaj ^b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c UNIVERSITY OF URUGUAY   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BRITISH AMYLOIDOSIS RELATED PEPTIDE; IMMUNOMODULATING AGENT; OLIGOMER; UNCLASSIFIED DRUG; ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DETERMINATION; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LOCOMOTION; MAZE TEST; MOUSE; NONHUMAN; PAIRED HELICAL FILAMENT; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN TARGETING; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE; ANIMAL; ASTROCYTE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; ROTAROD TEST; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ASTROCYTES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; LOCOMOTION; MAZE LEARNING; MICE; MICROGLIA; PROTEIN CONFORMATION; ROTAROD PERFORMANCE TEST;

EID: 78149424228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013391     Document Type: Article

References (52)

1. Perl DP (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77: 32-42.
2. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116: 1111-1162.
3. Rostagno A, Holton JL, Lashley T, Revesz T, Ghiso J (2010) Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci 67: 581-600.
4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurol 69: 2197-2204.
5. van der ZJ, Sleegers K, Van BC (2008) Invited article: the Alzheimer diseasefrontotemporal lobar degeneration spectrum. Neurol 71: 1191-1197.
6. Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, et al. (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurol 70: 1850-1857.
7. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 147: 238-244.
8. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
9. Wisniewski T, Boutajangout A (2010) Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct 214: 201-218.
10. Wisniewski T, Chabalgoity JA, Goni F (2007) Is vaccination against transmissible spongiform encephalopathies feasible? OIE Sci Tech Rev 26: 243-251.
11. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Ab immunization (AN1792) in patients with AD in an interupted trial. Neurol 64: 1553-1562.
12. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets 8: 65-81.
13. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299.
14. Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, et al. (2007) Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 282: 11436-11445.
15. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, et al. (2007) Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 282: 22376-22386.
16. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, et al. (1999) A stopcodon mutation in the BRI gene associated with familial British dementia. Nature 399: 776-781.
17. Rostagno A, Tomidokoro Y, Lashley T, Ng D, Plant G, et al. (2005) Chromosome 13 dementias. Cell Mol Life Sci 62: 1814-1825.
18. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 4: 97-100.
19. Vidal R, Barbeito AG, Miravalle L, Ghetti B (2009) Cerebral Amyloid Angiopathy and Parenchymal Amyloid Deposition in Transgenic Mice Expressing the Danish Mutant Form of Human BRI(2). Brain Pathol 19: 58-68.
20. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, et al. (2004) Blocking the apolipoprotein E/ß-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am J Pathol 165: 937-948.
21. Toumadje A, Alcorn SW, Johnson C (1992) Extending CD spectra of proteins to 168 nm improves the analysis for secondary structures. Anal Biochem 200: 321-331.
22. Sreerma N, Woody RW (1993) A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem 209: 32-44.
23. Kascsak RJ, Tonna-DeMasi M, Fersko R, Rubenstein R, Carp RI, et al. (1993) The role of antibodies to PrP in the diagnosis of transmissible spongiform encephalopathies. Dev Biol Stand 80: 141-151.
24. Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F, et al. (2006) Blocking the apolipoproteinE/Amyloid b interaction reduces the parenchymal and vascular amyloid-b deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci (USA) 103: 18787-18792.
25. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, et al. (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6: 231-244.
26. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li Y, et al. (2008) A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micromagnetic resonance imaging. J Neurosci Res 86: 2784-2791.
27. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, et al. (2006) Ab derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur J Neurosci 24: 2530-2542.
28. Goni F, Knudsen EL, Schreiber F, Scholtzova H, Pankiewicz J, et al. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neurosci 133: 413-421.
29. Sigurdsson EM, Knudsen EL, Asuni A, Sage D, Goni F, et al. (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-b derivatives. J Neurosci 24: 6277-6282.
30. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, et al. (2009) Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J Neurosci 29: 1846-1854.
31. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28: 8354-8360.
32. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64: 743-753.
33. Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, et al. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39: 669-673.
34. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
35. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639-29643.
36. Dhenain M, Delatour B, Walczak C, Volk A (2006) Passive staining: a novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease. Magn Reson Med 55: 687-693.
37. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, et al. (2009) Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 163: 55-72.
38. Wisniewski T, Sigurdsson EM (2010) Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta Mol Basis Dis 1802: 847-859.
39. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, et al. (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183-195.
40. Ito K, Ishibashi K, Tomiyama T, Umeda T, Yamamoto K, et al. (2009) Oligomeric amyloid beta-protein as a therapeutic target in Alzheimer's disease: its significance based on its distinct localization and the occurrence of a familial variant form. Curr Alzheimer Res 6: 132-136.
41. Lublin AL, Gandy S (2010) Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. Mt Sinai J Med 77: 43-49.
42. Ghiso J, Vidal R, Rostagno A, Miravalle L, Holton JL, et al. (2000) Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. Molecular Basis of Dementia 920: 84-92.
43. Srinivasan R, Jones EM, Liu K, Ghiso J, Marchant RE, et al. (2003) pHdependent amyloid and protofibril formation by the ABri peptide of familial British dementia. J Mol Biol 333: 1003-1023.
44. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
45. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
46. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochem 39: 10831-10839.
47. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499-509.
48. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, et al. (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-14545.
49. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De BP, et al. (2009) Betaamyloid monomers are neuroprotective. J Neurosci 29: 10582-10587.
50. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's Disease-Associated Amyloid beta-Protein Is an Antimicrobial Peptide. PLoS ONE 5: e9505.
51. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. (2010) (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372.
52. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long term effects of Ab42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function. Lancet 372: 216-223.